<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Atherogenic shift in blood <z:chebi fb="23" ids="18059">lipid</z:chebi> spectrum, which may manifest by the increase of serum levels of <z:chebi fb="0" ids="16113">cholesterin</z:chebi>, <z:chebi fb="2" ids="39026">low-density lipoproteins</z:chebi> (<z:chebi fb="15" ids="39026">LDL</z:chebi>), <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, very-low-density proteins (<z:chebi fb="1" ids="39027">VLDL</z:chebi>) or the decrease of serum levels of antiatherogenic <z:chebi fb="6" ids="39025">high-density lipoproteins</z:chebi> (<z:chebi fb="17" ids="39025">HDL</z:chebi>), is one of the leading risk factors of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> often have <z:mpath ids='MPATH_458'>normal</z:mpath> or subnormal level of <z:chebi fb="0" ids="16113">cholesterin</z:chebi> together with <z:hpo ids='HP_0002155'>hypertriglyceridemia</z:hpo> or no <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>) together with decreased serum level of <z:chebi fb="17" ids="39025">HDL</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Among <z:hpo ids='HP_0004929'>coronary atherosclerosis</z:hpo> (CorA), cerebral <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> (CA) and multifocal <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> the first condition has been explored more than the others, whose ethiopathogenic features has not been sufficiently studied yet </plain></SENT>
<SENT sid="3" pm="."><plain>However, sufficient knowledge of ethiopathogenic features of atherosclerotic process in various blood vessel basins would allow revealing the so called predictors of multifocal lesions and carrying out their timely prophylaxis or inhibiting their progression </plain></SENT>
<SENT sid="4" pm="."><plain>Investigation of <z:chebi fb="23" ids="18059">lipid</z:chebi> exchange showed that the most atherogenic alterations are characteristic of CorA and multifocal <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>CA is characterized chiefly by <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> type IV, while HP type II is more typical of CorA and multifocal <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="4" ids="17855">Triglycerides</z:chebi> have been demonstrated to influence mostly the progress of CA while <z:chebi fb="15" ids="39026">LDL</z:chebi> chiefly promote the dissemination of CorA </plain></SENT>
</text></document>